Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival.

Sebastian Michels,Jeremy Franklin,Bartomeu Massuti,Martin Sebastian,Hans-Ulrich Schildhaus,Enriqueta Felip,Christian Grohé,Delvys Rodriguez Abreu,Helge Bischoff,Enric Carcereny,Jesús Corral,Anne-Marie C. Dingemans,Amelia Insa,Martin Reck,Sacha I. Rothschild,Egbert F. Smit,Mariano Provencio,Reinhard Büttner,Rafael Rosell,Juergen Wolf

Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival.

2019

9066Background: ROS1 rearrangements are found in 1% of non-small cell lung cancer (NSCLC) patients. Early clinical trials in the US and East Asia have proven the therapeutic efficacy of crizotinib ...

Keywords:

Clinical trial
Lung cancer
Pathology
Crizotinib
Oncology
Internal medicine
Medicine
ROS1
in patient
overall survival
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations